semaglutide patent protection Semaglutide's expires today. What does it mean for patients, pharma players and Novo Nordisk? What is the patent landscape

The concentration on your vial label determines everything

A study conducted by 4.2 Body weight loss Patients with T2DM treated with certain GLP-1RAs have reported experiencing weight loss ( It was found that there was no significant difference in weight modification between the use of Tirzepatide at a dosage of 15 mg once weekly and Semaglutide at a dosage of 1 mg once a week

Week 14: Rapid appetite suppression + increased energy expenditure Month 13: Fastest fat loss of any studied GLP-1 class Month 36: Largest body composition shifts in trials 4872 weeks: Average 2430% total body weight reduction Ask our San Ramon team about retatrutide availability at your consultation

In general, being at a healthy weight equates to a healthier microbiome: Weight loss has been associated with more bacterial diversity and a better balance of good bacteria in the gut

Great service and product

Novo Nordisk Receives FDA Approval of OZEMPIC (Semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes